Rituximab therapy in severe connective tissue disease- associated interstitial lung disease: A retrospective single-centre observational study
Article Sidebar
Main Article Content
Abstract
Background. Connective tissue disease-associated interstitial lung disease (CTD-ILD) that progresses despite first-line immunosuppressive therapy is a clinical challenge. Rituximab (RTX) is a chimeric monoclonal antibody targeted to CD20+ B cells, resulting in B-cell depletion, and has been used as a salvage therapeutic modality in severe disease.
Objectives. To investigate the therapeutic effects and safety of RTX in patients with severe CTD-ILD.
Methods. A retrospective observational analysis of patients with severe CTD-ILD treated with salvage RTX therapy and various combinations of immunomodulatory therapy at Wits Donald Gordon Medical Centre, Johannesburg, South Africa, between January 2010 and December 2020 was performed. A total of 19 patients with progressive CTD-ILD, sufficient data, and 24-month follow-up were analysed. The effects of adding salvage RTX to standard drug therapy were investigated with serial pulmonary function testing, high-resolution computed tomography (HRCT) of the chest, and World Health Organization functional class (FC) assessment.
Results. At 24-month follow-up from baseline, there was no significant deterioration in forced vital capacity (0.01 L; 95% CI –0.13 - 0.14) (p=0.91) after commencing RTX salvage therapy. Serial HRCT of the chest showed radiological disease stability or improvement in 13 of the 19 patients (68%). FC assessment showed no significant deterioration compared with baseline (p=0.083). No serious adverse drug reactions or deaths were recorded.
Conclusion. Salvage RTX therapy, in combination with various immunomodulatory treatments, resulted in disease stability in the majority of patients with severe CTD-ILD over a 24-month period.
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
1. Oliveira RP, Ribeiro R, Melo L, Grima B, Oliveira S, Alves JD. Connective tissue disease-associated interstitial lung disease. Pulmonology 2022;28(2):113- 118. https://doi.org/10.1016/j.pulmoe.2020.01.004
2. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83(2):435-445.
3. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023;82(1):3-18. https://doi.org/10.1136/ ard-2022-223356
4. South African Health Products Regulatory Authority. Mabthera (rituximab), proposed package insert. https://www.sahpra.org.za/wp-content/ uploads/2020/02/MabThera_PI_Roche-Products_ MCC-format-02-October-2015.pdf (accessed 20 September 2021).5. Keir GJ, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: Rituximab as rescue therapy. Eur Respir J 2012;40(3):641-648. https:// doi.org/10.1183/09031936.00163911
6. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6):788-824. https://doi.org/10.1164/rccm.2009-040GL
7. Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): A double- blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021;9(5):476- 486. https://doi.org/10.1016/S2213-2600(20)30554-3
8. WellsAU,FlahertyKR,BrownKK,etal.Nintedanibinpatientswithprogressivefibrosing interstitial lung diseases – subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020;8(5):453-460. https://doi.org/10.1016/S2213-2600(20)30036-9
9. Weill D. Lung transplantation: Indications and contraindications. J Thorac Dis 2018;10(7):4574-4587. https://doi.org/10.21037/jtd.2018.06.141
10. Sharp C, McCabe M, Dodds N, et al. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatology (Oxford) 2016;55(7):1318- 1324. https://doi.org/10.1093/rheumatology/kew195
11. Atienza-MateoB,Remuzgo-MartínezS,Prieto-PeñaD,etal.Rituximabinthetreatment of interstitial lung disease associated with autoimmune diseases: Experience from a single referral center and literature review. J Clin Med 2020;9(10):3070. https://doi. org/10.3390/jcm9103070
12. MaherTM,TudorVA,SaundersP,etal.Rituximabversusintravenouscyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): A double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 2023;11(1):45-54. https://doi.org/10.1016/S2213-2600(22)00359-9
13. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):40S-47S. https://doi.org/10.1016/j.jacc.2004.02.032
14. European Alliance of Associations for Rheumatology (EULAR). EULAR recommendations: EULAR/ACR collaborative projects. https://www.eular.org/ recommendations-eular-acr (accessed July 2023).
15. Rajan SK, Cottin V, Dhar R, et al. Progressive pulmonary fibrosis: An expert group consensus statement. Eur Respir J 2023;61(3):2103187. https://doi. org/10.1183/13993003.03187-2021
16. Roche Pharma. MabThera/Rituxin (rituximab). 2021. https://www.roche.com/ products/product-details.htm?productId=b0eb216f-addf-4ed1-b01e-0b12fe0b1ef6 (accessed 20 September 2021).
17. Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: Interstitial pneumonia with autoimmune features. Eur Respir J 2015;46(4):976-987. https://doi. org/10.1183/13993003.00150-2015
18. Fischer A, Distler J. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clin Rheumatol 2019;38(10):2673-2681. https://doi. org/10.1007/s10067-019-04720-0
19. Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: Comorbidity and mortality. Ann Rheum Dis 2017;76(10):1700-1706. https://doi.org/10.1136/ annrheumdis-2017-211138
20. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165(12):1581-1586. https://doi.org/10.1164/rccm.2106012
21. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013;143(3):814-824. https://doi.org/10.1378/ chest.12-0741